Expression of angiogenic factors in hepatocarcinogenesis: Identification by antibody arrays

Nomura,Takako; Morishita,Asahiro; Jian,Gong; Mimura,Shima; Kato,Kiyohito; Nomura,Kei; Tani,Joji; Miyoshi,Hisaaki; Yoneyama,Hirohito; Sakamoto,Teppei; Fujita,Koji; Maeda,Emiko; Kobara,Hideki; Mori,Hirohito; Iwama,Hisakazu; Masaki,Tsutomu

doi:10.3892/or.2013.2674

Expression of angiogenic factors in hepatocarcinogenesis: Identification by antibody arrays

Authors:
- Takako Nomura
- Asahiro Morishita
- Gong Jian
- Shima Mimura
- Kiyohito Kato
- Kei Nomura
- Joji Tani
- Hisaaki Miyoshi
- Hirohito Yoneyama
- Teppei Sakamoto
- Koji Fujita
- Emiko Maeda
- Hideki Kobara
- Hirohito Mori
- Hisakazu Iwama
- Tsutomu Masaki
View Affiliations

Affiliations: Department of Gastroenterology and Neurology, Kagawa University School of Medicine, Miki-cho, Kita-gun, Kagawa 761-0793, Japan, Information Technology Center, Kagawa University School of Medicine, Miki-cho, Kita-gun, Kagawa 761-0793, Japan
Published online on: August 20, 2013 https://doi.org/10.3892/or.2013.2674
Pages: 2476-2480

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiogenesis plays a pivotal role in the progression and metastasis of hepatocellular carcinoma (HCC). However, the expression of a wide range of angiogenic factors remains obscure in HCC. The purpose of the present study was to determine the expression of various angiogenic factors related to hepatocarcinogenesis. We examined the expression of 19 angiogenic factors using antibody arrays in human tissues of various liver diseases, including HCC. We also studied the expression of 19 angiogenic factors in the human HCC cell lines PLC/PRF/5, Hep 3B, HuH7, HLE, HLF and Li-7 and the normal hepatocyte cell line ACBRI3716. In human tissues, although the expression of acidic fibroblast growth factor (aFGF) was found to increase from normal liver to chronic hepatitis, its expression remained unchanged in the transition from chronic hepatitis to HCC. Vascular endothelial growth factor (VEGF) was elevated in liver cirrhosis, but the amounts remained unchanged in the transition from liver cirrhosis to HCC. In contrast, either interleukin-8 (IL-8) or basic fibroblast growth factor (bFGF) was upregulated in HCC. In the HCC cell lines PLC/PRF/5, Hep 3B and HuH-7, the expression of IL-8 was elevated. Although IL-8 was not elevated, bFGF was upregulated in the other HCC cell lines HLE, HLF and Li-7. Thus, either IL-8 or bFGF was upregulated in HCC cell lines and in HCC tissue samples. These data suggest that the upregulation of either IL-8 or bFGF is closely related to the transition from liver cirrhosis into HCC. Therefore, the analysis of the expression of these cytokines using protein arrays may identify novel therapies for individual patients with HCC.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Blum HE: Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 11:7391–7400. 2005.PubMed/NCBI
3	Portolani N, Coniglio A, Ghidoni S, et al: Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 243:229–235. 2006. View Article : Google Scholar : PubMed/NCBI
4	Poon RT and Fan ST: Resection prior to liver transplantation for hepatocellular carcinoma: a strategy of optimizing the role of resection and transplantation in cirrhotic patients with preserved liver function. Liver Transpl. 10:813–815. 2004. View Article : Google Scholar : PubMed/NCBI
5	Grepin R and Pages G: Molecular mechanisms of resistance to tumour anti-angiogenic strategies. J Oncol. 2010:8356802010. View Article : Google Scholar : PubMed/NCBI
6	Sanz-Cameno P, Trapero-Marugan M, Chaparro M, Jones EA and Moreno-Otero R: Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma. J Oncol. 2010:2721702010. View Article : Google Scholar : PubMed/NCBI
7	Naumov GN, Folkman J and Straume O: Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin Exp Metastasis. 26:51–60. 2009. View Article : Google Scholar : PubMed/NCBI
8	Zappala G, McDonald PG and Cole SW: Tumor dormancy and the neuroendocrine system: an undisclosed connection? Cancer Metastasis Rev. 32:189–200. 2013. View Article : Google Scholar : PubMed/NCBI
9	Hisai H, Kato J, Kobune M, et al: Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity. Clin Cancer Res. 9:4852–4859. 2003.PubMed/NCBI
10	Pang R and Poon RT: Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett. 242:151–167. 2006. View Article : Google Scholar : PubMed/NCBI
11	Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:248–254. 1976. View Article : Google Scholar : PubMed/NCBI
12	Crowther JR: ELISA. Theory and practice Methods. Mol Biol. 42:1–218. 1995.PubMed/NCBI
13	Moserle L and Casanovas O: Anti-angiogenesis and metastasis: a tumour and stromal cell alliance. J Intern Med. 273:128–137. 2013. View Article : Google Scholar : PubMed/NCBI
14	Rak J and Klement G: Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer. Cancer Metastasis Rev. 19:93–96. 2000. View Article : Google Scholar : PubMed/NCBI
15	Sun HC and Tang ZY: Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol. 130:307–319. 2004. View Article : Google Scholar : PubMed/NCBI
16	Schwartz M, Roayaie S and Konstadoulakis M: Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 4:424–432. 2007. View Article : Google Scholar : PubMed/NCBI
17	Qazi BS, Tang K and Qazi A: Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis. Int J Inflam. 2011:9084682011.PubMed/NCBI
18	Teicher BA: Antiangiogenic agents and targets: A perspective. Biochem Pharmacol. 81:6–12. 2011. View Article : Google Scholar : PubMed/NCBI
19	Hussain F, Wang J, Ahmed R, et al: The expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas and pancreatic neuroendocrine tumours. Cytokine. 49:134–140. 2010. View Article : Google Scholar : PubMed/NCBI
20	Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD and Strieter RM: Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest. 97:2792–2802. 1996. View Article : Google Scholar : PubMed/NCBI
21	Moore BB, Arenberg DA, Stoy K, et al: Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol. 154:1503–1512. 1999. View Article : Google Scholar : PubMed/NCBI
22	Ishii Y, Sakamoto T, Ito R and Yanaga K: Anti-angiogenic therapy on hepatocellular carcinoma development and progression. J Surg Res. 158:69–76. 2010. View Article : Google Scholar : PubMed/NCBI
23	Poon RT, Ng IO, Lau C, Yu WC, Fan ST and Wong J: Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg. 182:298–304. 2001. View Article : Google Scholar
24	Yoshiji H, Kuriyama S, Yoshii J, et al: Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology. 35:834–842. 2002. View Article : Google Scholar : PubMed/NCBI
25	De Luca A, Carotenuto A, Rachiglio A, et al: The role of the EGFR signaling in tumor microenvironment. J Cell Physiol. 214:559–567. 2008.PubMed/NCBI
26	Normanno N, Bianco C, De Luca A, Maiello MR and Salomon DS: Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer. 10:1–21. 2003. View Article : Google Scholar : PubMed/NCBI
27	Liu S, Gong J, Morishita A, et al: Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma. Exp Ther Med. 2:399–403. 2011.PubMed/NCBI